Source-grounded facts extracted from JOHNSON & JOHNSON's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
JOHNSON & JOHNSON reported first quarter ended March 29, 2026 results: revenue $24,062, net income $5,235, EPS $2.14.
“5,110 14.5 2.7 11.8 Western Hemisphere excluding U.S. 1,293 1,167 10.8 2.5 8.3 Asia-Pacific, Africa 3,591 3,311 8.5 6.1 2.4 International 10,732 9,588 11.9 3.9 8.0 Worldwide $24,062 21,893 9.9 % 6.4 3.5 Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. Johnson & Johnson and subsidiaries”
D. Adamczyk departed as Director at JOHNSON & JOHNSON.
“D. Adamczyk notified the Company that he intends to retire from the Company’s Board of Directors in connection with an announcement on April 23 rd that he will join Goldman Sachs as a Partner.”
D. S. Davis retired as Director at JOHNSON & JOHNSON.
“On September 10, 2024, D. S. Davis retired as a Director of Johnson & Johnson after the successful transition of Audit Committee Chair responsibilities to D. Adamczyk.”
Peter M. Fasolo departed as Executive Vice President, Chief Human Resources Officer at JOHNSON & JOHNSON.
“On August 26, 2024, Johnson & Johnson (the Company) issued a press release announcing that Peter M. Fasolo, Executive Vice President, Chief Human Resources Officer (CHRO), has elected to retire.”
JOHNSON & JOHNSON reported first quarter ended March 31, 2024 results: revenue $21,383, net income $3,255, EPS $1.34.
“(Unaudited; in Millions Except Per Share Figures) FIRST QUARTER 2024 2023 Percent Percent Percent Increase Amount to Sales Amount to Sales (Decrease) Sales to customers $ 21,383 100.0 $ 20,894 100.0 2.3 Cost of products sold 6,511 30.4 6,687 32.0 (2.6) Gross Profit 14,872 69.6 14,207 68.0 4.7 Selling, marketing and administrative expenses 5,257 24.6 4,906”
JOHNSON & JOHNSON: Amended and restated by-laws effective April 25, 2024, with updates to special meeting requests, shareholder meeting conduct, voting standard, advance notice and proxy access provisions, CEO President clarification, and indemnification provisions (effective 2024-04-25).
“On April 25, 2024, the Board of Directors (the “Board”) of Johnson & Johnson (the “Company”) approved and adopted amended and restated by-laws of the Company (the “Amended and Restated By-Laws”), effective as of such date.”
JOHNSON & JOHNSON shareholders rejected Shareholder Proposal - gender-based compensation gaps and associated risks at the 2024-04-25 meeting.
“4. Shareholder Proposal - gender-based compensation gaps and associated risks: For Against Abstained Non-Votes 64,871,020.00 1,595,866,856.00 19,184,907.00 338,170,891.00”
JOHNSON & JOHNSON shareholders approved Ratification of appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for 2024 at the 2024-04-25 meeting.
“3. Ratification of appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for 2024 : For Against Abstained Non-Votes 1,896,186,129.00 117,320,388.00 4,587,157.00 0”
JOHNSON & JOHNSON shareholders approved Advisory vote to approve named executive officer compensation (Say on Pay) at the 2024-04-25 meeting.
“2. Advisory vote to approve named executive officer compensation (Say on Pay): For Against Abstained Non-Votes 1,511,199,544.00 159,356,373.00 9,366,866.00 338,170,891.00”
JOHNSON & JOHNSON shareholders approved Election of Directors at the 2024-04-25 meeting.
“1. Election of Directors: Shares For Shares Against Shares Abstain Non-Votes D. Adamczyk 1,656,623,584 18,925,478 4,373,721 338,170,891 M. C. Beckerle 1,663,236,710 12,988,890 3,697,183 338,170,891 D. S. Davis 1,637,607,236 38,041,198 4,274,349 338,170,891 J. A. Doudna 1,663,406,168 12,832,643 3,683,972 338,170,891 J. Duato 1,561,512,061 109,541,207 8,869,515 338,170,891 M. A. Hewson 1,631,542,950 44,419,702 3,960,131 338,170,891 P. A. Johnson 1,662,656,052 13,581,894 3,684,837 338,170,891 H. Joly 1,656,506,211 19,141,858 4,274,714 338,170,891 M. B. McClellan 1,661,933,030 13,974,677 4,015,076 338,170,891 A. M. Mulcahy 1,624,143,536 52,044,434 3,734,813 338,170,891 M. A. Weinberger 1,651,183,425 24,483,916 4,255,442 338,170,891 N. Y. West 1,666,853,163 9,240,391 3,829,229 338,170,891 E. A. Woods 1,665,190,129 10,460,172 4,272,482 338,170,891”
JOHNSON & JOHNSON reported first quarter ended March 31, 2024 results: revenue $21,383 million, net income $5,354 million, EPS $2.20.
“On April 16, 2024, Johnson & Johnson issued the attached press release (Exhibit 99.1) announcing its sales and earnings for the first quarter ended March 31, 2024.”
Eugene A. Woods was elected as Director at JOHNSON & JOHNSON.
“On November 30, 2023, Johnson & Johnson (the “Company” or “Johnson & Johnson”) announced that Eugene A. Woods, MBA, MHA, was elected to the Board of Directors.”
Ashley McEvoy resigned as Executive Vice President, Worldwide Chair MedTech at JOHNSON & JOHNSON.
“Ashley McEvoy resigned from her position as Executive Vice President, Worldwide Chair MedTech and member of the Executive Committee effective October 20, 2023”
JOHNSON & JOHNSON updated its guidance (raised).
“Johnson & Johnson completed an exchange offer to finalize the separation of Kenvue Inc. (the "Kenvue Separation"). On August 30, 2023, Johnson & Johnson issued the attached press release (Exhibit 99.1) providing updated financials and 2023 guidance following completion of the Kenvue Separation.”
JOHNSON & JOHNSON completed a disposition involving Johnson & Johnson shareholders (closed 2023-08-23).
“On August 23, 2023, Johnson & Johnson completed its previously announced split-off exchange offer of 1,533,830,450 shares of common stock of Kenvue Inc. (“Kenvue”), pursuant to which Johnson & Johnson accepted an aggregate of 190,955,435 shares of Johnson & Johnson common stock from its shareholders in exchange for 1,533,830,450 shares of Kenvue common stock owned by Johnson & Johnson.”
JOHNSON & JOHNSON reported second quarter ended July 2, 2023 results: revenue $25.5 Billion, net income $5,144, EPS $1.96. Guidance raised.
“the second quarter ended July 2, 2023. --- EX-99.1 (EX-99.1) --- JOHNSON & JOHNSON REPORTS 2023 SECOND-QUARTER RESULTS: • 2023 Second-Quarter reported sales growth of 6.3% to $25.5 Billion with operational growth of 7.5%* and adjusted operational growth of 6.2%*. Operational growth excluding COVID-19 Vaccine of 8.9%* • Earnings per share (EPS) of $1.96 increasing”
JOHNSON & JOHNSON entered into Separation Agreement with Kenvue Inc. (effective 2023-05-03).
“On May 8, 2023, Kenvue Inc., a Delaware corporation (“Kenvue”), completed its previously announced initial public offering (the “IPO”) of 198,734,444 shares of its common stock, par value $0.01 per share (the “Kenvue Common Stock”), including the underwriters’ full exercise of their option to purchase 25,921,884 shares to cover over-allotments, at an initial public offering price of $22.00 per share for net proceeds of $4,241 million.”
JOHNSON & JOHNSON shareholders rejected Shareholder Proposal - Impact of Extended Patent Exclusivities on Product Access at the 2023-04-27 meeting.
“Shareholder Proposal - Impact of Extended Patent Exclusivities on Product Access: For Against Abstained Non-Votes 258,032,003 1,530,773,877 30,867,151 353,172,322”
JOHNSON & JOHNSON shareholders rejected Shareholder Proposal - Vaccine Pricing Report at the 2023-04-27 meeting.
“Shareholder Proposal - Vaccine Pricing Report: For Against Abstained Non-Votes 569,515,836 1,223,800,230 26,356,965 353,172,322”
JOHNSON & JOHNSON shareholders approved Ratification of Appointment of PricewaterhouseCoopers LLP as the Company's Independent Registered Public Accounting Firm for 2023 at the 2023-04-27 meeting.
“Ratification of Appointment of PricewaterhouseCoopers LLP as the Company's Independent Registered Public Accounting Firm for 2023 : For Against Abstained Non-Votes 2,048,852,179 118,621,657 5,371,517 (0)”
JOHNSON & JOHNSON shareholders approved Advisory Vote on the Frequency of Voting to Approve Named Executive Officer Compensation at the 2023-04-27 meeting.
“Advisory Vote on the Frequency of Voting to Approve Named Executive Officer Compensation: For 1 Year For 2 Years For 3 Years Abstained Non-Votes 1,785,566,411 4,955,319 22,089,730 7,061,571 353,172,322”
JOHNSON & JOHNSON shareholders approved Advisory Vote to Approve Named Executive Officer Compensation at the 2023-04-27 meeting.
“Advisory Vote to Approve Named Executive Officer Compensation: For Against Abstained Non-Votes 1,685,320,654 123,275,647 11,076,730 353,172,322”
JOHNSON & JOHNSON shareholders approved Election of Directors at the 2023-04-27 meeting.
“Election of Directors: Shares For Shares Against Shares Abstain Non-Votes D. Adamczyk 1,786,272,387 16,426,067 16,974,577 353,172,322 M. C. Beckerle 1,789,457,274 13,764,941 16,450,816 353,172,322 D. S. Davis 1,756,303,275 46,470,790 16,898,966 353,172,322 J. A. Doudna 1,789,027,330 14,257,035 16,388,666 353,172,322 J. Duato 1,688,009,715 120,870,955 10,792,361 353,172,322 M. A. Hewson 1,773,472,628 29,649,436 16,550,967 353,172,322 P. A. Johnson 1,804,950,345 9,856,598 4,866,088 353,172,322 H. Joly 1,772,344,027 30,395,092 16,933,912 353,172,322 M. B. McClellan 1,788,586,733 14,265,282 16,821,016 353,172,322 A. M. Mulcahy 1,698,043,017 104,917,215 16,712,799 353,172,322 M. A. Weinberger 1,788,359,732 14,280,263 17,033,036 353,172,322 N. Y. West 1,793,769,456 9,125,005 16,778,570 353,172,322”
Thibaut Mongon departed as Executive Vice President, Worldwide Chairman, Consumer Health at JOHNSON & JOHNSON.
“Upon the closing of the initial public offering of Kenvue Inc., Thibaut Mongon will cease to be Executive Vice President, Worldwide Chairman, Consumer Health and member of the Executive Committee of Johnson & Johnson and will continue his role as Chief Executive Officer of Kenvue Inc.”
JOHNSON & JOHNSON reported first quarter ended April 2, 2023 results: revenue $24.7 Billion, net income ($0.03), EPS $2.68. Guidance raised.
“JOHNSON & JOHNSON REPORTS 2023 FIRST-QUARTER RESULTS: • 2023 First-Quarter reported sales growth of 5.6% to $24.7 Billion with operational growth of 9.0%* and adjusted operational growth of 7.6%* • 2023 First-Quarter basic loss per share of ($0.03) decreasing 101.6% due to a special one-time charge, with adjusted earnings per share (EPS) of $2.68 increasing by 0.4%* • Company is increasing 2023 full-year guidance midpoints for adjusted operational sales and adjusted operational EPS”
Ian E. L. Davis retired as Director at JOHNSON & JOHNSON.
“On March 31, 2023, Ian E. L. Davis retired as a Director of Johnson & Johnson.”
Paula A. Johnson was appointed as Member of the Board of Directors at JOHNSON & JOHNSON.
“Johnson & Johnson (the “Company”) announced on February 14, 2023, that Paula A. Johnson, President of Wellesley College, has been appointed to its Board of Directors (the “Board”), effective immediately.”
Paula A. Johnson was appointed as Director at JOHNSON & JOHNSON.
“Johnson & Johnson (the “Company”) announced on February 14, 2023, that Paula A. Johnson, Chairman and Chief Executive Officer of Honeywell, has been appointed to its Board of Directors (the “Board”), effective immediately.”
JOHNSON & JOHNSON reported 2023 results: revenue 4.0%, EPS $10.50. Guidance initiated.
“Company guides 2023 adjusted operational sales growth excluding COVID-19 Vaccine of 4.0%* and adjusted operational EPS of $10.50, reflecting growth of 3.5%*”
JOHNSON & JOHNSON reported the fiscal year ended January 1, 2023 results: revenue $94.9 Billion, EPS $6.73.
“• 2022 Full-Year reported sales growth of 1.3% to $94.9 Billion primarily driven by strong commercial execution partially offset by unfavorable foreign exchange. Operational growth of 6.1%* • 2022 Full-Year earnings per share (EPS) of $6.73 decreasing 13.8% and adjusted EPS of $10.15 increasing by 3.6%*”
JOHNSON & JOHNSON reported the fourth quarter ended January 1, 2023 results: revenue $23.7 Billion, EPS $1.33.
“• 2022 Fourth-Quarter reported sales decline of 4.4% to $23.7 Billion primarily driven by unfavorable foreign exchange and reduced COVID-19 Vaccine sales vs. prior year. Operational growth excluding COVID-19 Vaccine of 4.6%* • 2022 Fourth-Quarter earnings per share (EPS) of $1.33 decreasing 24.9% and adjusted EPS of $2.35 increasing by 10.3%*”
JOHNSON & JOHNSON completed an acquisition involving ABIOMED for approximately $17.1 billion (closed 2022-12-22).
“in each case, multiplied by the number of Shares underlying such ABIOMED RSU. The aggregate amount paid by Purchaser in the Offer and the Merger for the Shares was approximately $17.1 billion, excluding related fees and expenses. Johnson & Johnson and Purchaser funded the acquisition of the Shares in the Offer and the Merger through a combination of Johnson &”
JOHNSON & JOHNSON entered into Contingent Value Rights Agreement with American Stock Transfer & Trust Company, LLC valued at Each CVR represents the non-tradeable contractual right to receive contingent cash payments of up to (effective 2022-12-22).
“on December 22, 2022, Johnson & Johnson and American Stock Transfer & Trust Company, LLC, a New York limited liability trust company, entered into a Contingent Value Rights Agreement (the “ CVR Agreement ”) governing the terms of the CVRs (as defined below) issued pursuant to the Offer and the Merger (as defined below).”
Joaquin Duato was elected as Chairman at JOHNSON & JOHNSON.
“the Company announced that its Board of Directors elected Joaquin Duato Chairman, Board of Directors of Johnson & Johnson effective upon current Chairman Alex Gorsky’s retirement from the Board of Directors.”
Alex Gorsky departed as Chairman at JOHNSON & JOHNSON.
“Current Chairman Alex Gorsky will step down from the Board in January 2023, following a brief transition period and will not stand for reelection in 2023.”
JOHNSON & JOHNSON entered into Agreement and Plan of Merger with ABIOMED, Inc. valued at Johnson & Johnson to acquire all outstanding shares of ABIOMED for $380.00 per share in cash plus on (effective 2022-10-31).
“Item 1.01 Entry into a Material Definitive Agreement Agreement and Plan of Merger On October 31, 2022, Johnson & Johnson, a New Jersey corporation (“ Johnson & Johnson ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Athos Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Johnson & Johnson (“ Merger Sub ”), and ABIOMED, Inc., a Delaware corporation (“ ABIOMED ”).”
Darius Adamczyk was appointed as Director at JOHNSON & JOHNSON.
“Johnson & Johnson (the “Company”) announced on February 15, 2022, that Darius Adamczyk, Chairman and Chief Executive Officer of Honeywell, has been appointed to its Board of Directors (the “Board”), effective immediately.”
Alex Gorsky changed role as Executive Chairman at JOHNSON & JOHNSON.
“Alex Gorsky, previously Chairman and CEO of the Company, transitioned to Executive Chairman of the Company”
Joaquin Duato was appointed as Member of the Board of Directors at JOHNSON & JOHNSON.
“has been appointed as a member of the Company’s Board of Directors”
Joaquin Duato changed role as Chief Executive Officer at JOHNSON & JOHNSON.
“Joaquin Duato, previously Vice Chairman of the Company’s Executive Committee, assumed the role of Chief Executive Officer (“CEO”) of the Company and has been appointed as a member of the Company’s Board of Directors”
Paul Stoffels retired as Vice Chairman of the Executive Committee and Chief Scientific Officer at JOHNSON & JOHNSON.
“On October 12, 2021, Johnson & Johnson (the “Company”) issued a press release announcing that Paul Stoffels, Vice Chairman of the Executive Committee and Chief Scientific Officer, has elected to retire, effective December 31, 2021.”
Joaquin Duato was appointed as Director at JOHNSON & JOHNSON.
“Mr. Duato will be appointed a Director of the Board, effective January 3, 2022;”
Joaquin Duato was appointed as Chief Executive Officer at JOHNSON & JOHNSON.
“Joaquin Duato will become CEO of the Company, effective January 3, 2022;”
Alex Gorsky changed role as Executive Chairman at JOHNSON & JOHNSON.
“Alex Gorsky, currently Chairman and Chief Executive Officer (“CEO”) of the Company, will relinquish the CEO position, effective January 3, 2022, and will continue his service on the Board as Executive Chairman.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.